Physician profile
William M Hendricks
NPI 1245791722
$13,443.03
in general payments reported to CMS, 2019-2025
27 companies · $3,570 in 2025
The $3,570 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,863 · 2022: $2,321 · 2023: $2,610 · 2024: $3,080 · 2025: $3,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,168 · Education: $91.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,167.89 |
| Education | $91.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,875.54 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,270.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,217.77 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,150.72 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $846.81 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $815.85 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $631.35 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $608.71 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $489.37 | 2021-2025 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $488.15 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $479.29 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $424.78 | 2021-2025 | Rexulti |
| Almatica Pharma LLC | $382.84 | 2021-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $308.58 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $248.52 | 2022-2024 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $246.18 | 2024-2025 | Cobenfy |
| Corium, LLC | $243.93 | 2023-2025 | Azstarys, Azstarys |
| Merck Sharp & Dohme LLC | $185.25 | 2021-2023 | Belsomra |
| Sunovion Pharmaceuticals INC. | $169.09 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $87.21 | 2022-2023 | Qelbree |
| Acadia Pharmaceuticals INC | $73.84 | 2025 | Nuplazid |
| Tris Pharma INC | $63.55 | 2022-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $45.93 | 2023-2025 | Abilify Asimtufii |
| Eisai INC. | $30.80 | 2021 | |
| Depuy Synthes Sales INC. | $19.74 | 2022 | |
| Avanir Pharmaceuticals, INC. | $19.72 | 2021 | |
| Noven Pharmaceuticals, INC. | $19.49 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hendricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.